

# SOCIAL GENOMIC MECHANISMS OF HEALTH DISPARITIES AMONG ADOLESCENT AND YOUNG ADULT (AYA) CANCER SURVIVORS (ECOG-ACRIN TRIAL EAQ211)

Funded in part by the National Cancer Institute, National Institutes of Health Division of Cancer Control and Population Sciences (DCCPS), Grant Number: 1R01CA61752-01; and ECOG-ACRIN NCORP RB grant number: UG1CA189828

## Specific Aims

#1: To identify the **genome-wide transcriptional impact** of **SOCIAL-ENVIRONMENTAL RISK factors** and define the relationships of those genomic profiles to AYA lymphoma survivor **OUTCOMES** (i.e., morbidity, mortality, QOL).

#2: To identify the **genome-wide transcriptional impact** of **INDIVIDUAL RESILIENCE factors** and define the relationships of those genomic profiles to AYA lymphoma survivor health **OUTCOMES** (i.e., morbidity, mortality, QOL).

#3: To examine disparities in these mechanisms as a function of race/ethnicity, sexual orientation and gender identification, and geography (urban/rural).


## Method

**Study Design:** Longitudinal prospective single cohort of AYAs recruited from community oncology settings, with repeated measures of two years


**Study Participants:** 2000 patients diagnosed with Hodgkin or Non-Hodgkin Lymphoma, recruited at completion of therapy – Recruitment through the ECOG-ACRIN Cancer Research Base and NCI Community Oncology Research Program (NCORP)

**Data Collection:** Patient-Reported Outcome (PRO) measures administered via survey; blood samples at baseline, 6-, 12-, 18-, and 24-month follow-up.

## Conceptual Framework: Social Genomics in Cancer Survivorship



## Data Analytic Framework



## Investigative Team

B Zebrack (PI),<sup>1</sup> S Cole,<sup>2</sup> JM Salsman,<sup>3</sup> L Wagner,<sup>4</sup> F Duan,<sup>5</sup> I Gareen,<sup>5</sup> SK Parsons,<sup>6</sup> A Evens,<sup>7</sup> C Cheung,<sup>8</sup> L Lux,<sup>4</sup> LV Ghazal,<sup>9</sup> P Prasad,<sup>10</sup> S Dinner<sup>11</sup>

## Affiliations

<sup>1</sup>University of Michigan; <sup>2</sup>David Geffen School of Medicine, UCLA; <sup>3</sup>Wake Forest School of Medicine; <sup>4</sup>University of North Carolina; <sup>5</sup>Brown University; <sup>6</sup>Tufts Cancer Center; <sup>7</sup>Rutgers Cancer Institute; <sup>8</sup>University of Maryland; <sup>9</sup>University of Rochester; <sup>10</sup>Louisiana State University; <sup>11</sup>Northwestern University

AYA Stakeholder Organizations: TeenCancerAmerica; Cactus Cancer; Leukemia and Lymphoma Society; Cervivor

Disclosures: Cole: BlueNote Therapeutics; Wagner: Johnson & Johnson, Lilly, Gilead Sciences, Celgene, Athenex; Parsons: Seattle Genetics; Prasad: Vertex; Dinner: Kite, Pfizer, Novartis



SCHOOL OF  
**SOCIAL WORK**  
UNIVERSITY OF MICHIGAN